Volume 26, Issue 4 (10-2024)
yafte 2024, 26(4): 1-12 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Tavakoli Z, Alamdary A, Fatahi S M, Birjandi M, Ajorloo M. Prevalence of Cytomegalovirus Infection among Patients with Cancer Receiving Chemotherapy in Khorramabad. yafte 2024; 26 (4) :1-12
URL: http://yafte.lums.ac.ir/article-1-3754-en.html
URL: http://yafte.lums.ac.ir/article-1-3754-en.html
Hepatitis Research Center, Department of Virology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran & Hepatitis Research Center, Department of Virology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
Abstract: (224 Views)
Background: Chemotherapy affects the immune system of cancer patients and makes them susceptible to opportunistic infections such as cytomegalovirus (CMV). In this study, the prevalence of CMV was investigated in cancer patients undergoing chemotherapy in Khorramabad city.
Materials and Methods: In this study, 235 people, including 96 women (40.9%) and 139 men (59.1%), were examined for IgM and IgG antibodies against CMV and PCR test. In the present study, the effects of type of cancer, duration of chemotherapy, age, gender and marital status on the prevalence of CMV were investigated.
Results: In this study, positive cases included 78.3% IgG, 3.8% IgM and 42.9% PCR. There was no significant relationship between the prevalence of CMV and the type of cancer, gender and marital status (P≥0.05). The frequency of positive IgG in the age group of 61-80 years was significantly higher than other age groups (P=0.01). The results of the PCR test showed that the prevalence of CMV was significantly higher in people undergoing longer chemotherapy (19-24 months compared to less than 6 months, P=0.001).
Conclusion: In the present study, there were positive cases in PCR test with negative serology results. Therefore, it is suggested to use the molecular test to confirm the serological assay. Also, a significant relationship between the duration of chemotherapy and the prevalence of CMV was observed. People with weakened immune systems, such as cancer patients undergoing chemotherapy, should be routinely evaluated for CMV in order to reduce complications related to this infection.
Materials and Methods: In this study, 235 people, including 96 women (40.9%) and 139 men (59.1%), were examined for IgM and IgG antibodies against CMV and PCR test. In the present study, the effects of type of cancer, duration of chemotherapy, age, gender and marital status on the prevalence of CMV were investigated.
Results: In this study, positive cases included 78.3% IgG, 3.8% IgM and 42.9% PCR. There was no significant relationship between the prevalence of CMV and the type of cancer, gender and marital status (P≥0.05). The frequency of positive IgG in the age group of 61-80 years was significantly higher than other age groups (P=0.01). The results of the PCR test showed that the prevalence of CMV was significantly higher in people undergoing longer chemotherapy (19-24 months compared to less than 6 months, P=0.001).
Conclusion: In the present study, there were positive cases in PCR test with negative serology results. Therefore, it is suggested to use the molecular test to confirm the serological assay. Also, a significant relationship between the duration of chemotherapy and the prevalence of CMV was observed. People with weakened immune systems, such as cancer patients undergoing chemotherapy, should be routinely evaluated for CMV in order to reduce complications related to this infection.
Type of Study: Research |
Received: 2024/07/24 | Accepted: 2024/10/22 | Published: 2024/10/31
Received: 2024/07/24 | Accepted: 2024/10/22 | Published: 2024/10/31
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
